Alan McCormick

Managing Director, Legatum

Alan McCormick is a founding Partner of the purpose-driven investment firm Legatum. He serves on the Board of Directors for the END Fund, and is Chairman for the Luminos Fund, the Legatum Institute and the Freedom Fund. Mr McCormick is also a supporter of many other causes that promote greater freedom and prosperity around the world.

Legatum is a global investment partnership that invests its proprietary capital in private and listed businesses and focuses its other energies on surfacing ideas and supporting initiatives that enable people, communities and nations to prosper.  Mr McCormick sits on the firm’s investment committee and has been particularly engaged with the group’s social investment portfolio.

Over the last decade, Mr McCormick and his Partners have founded several philanthropic funds, which include the END Fund, the largest private investment vehicle for eliminating Neglected Tropical Diseases (NTDs). Legatum started tackling NTDs in 2006, in Rwanda and Burundi, by trialling the first mass drug administration, which ultimately treated over 9.7 million people in four years. Seeing that NTDs affected over one billion of the world’s population, Legatum established the END Fund in 2012 as an independent vehicle to bring together private donors to accomplish one big goal: to see an end to the most prevalent NTDs once and for all.

Mr McCormick has been with Legatum since its founding in 2006. He was formerly part of Legatum’s predecessor, Sovereign Asset Management, and a member of its special situations team. Prior to that he worked for JP Morgan.